Quantitative MRI for structural and functional characterization of head and neck cancer for outcome prediction and biological individualization of MR-guided radiotherapy

用于头颈癌结构和功能表征的定量 MRI，用于 MR 引导放射治疗的结果预测和生物个体化

• 批准号: 437907809
• 负责人: Professor Dr. Konstantin Nikolaou
• 金额: --
• 依托单位: Radiologische Universitätsklinik (Department)
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2020
• 资助国家: 德国
• 起止时间: 2019-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/437907809?language=en
• 关键词: Quantitative; MRI; structural; functional; characterization

This research project focusses on quantitative magnetic resonance imaging (MRI) for structural and functional tumour characterisation using a hybrid 1.5 T MR-Linac system in head and neck cancer (HNC) patients. Imaging protocols and sequences will be developed to allow the assessment of MR-based quantitative imaging biomarkers (QIB) such as Apparent Diffusion Coefficient (ADC), T1-, T2- and T2*-mapping in HNC patients during fractionated radiotherapy (RT) at the MR-Linac. A test-retest patient study will be initiated to assess robustness, reproducibility and variability of all QIB as well as tumour volume before and during the course of RT. Furthermore, comparability of quantitative MRI measurements with state-of-the-art diagnostic MR scanners will be investigated. In the context of a subsequent clinical study, the ultimate goal of this project is to determine the QIB’s potential prognostic value with respect to RT outcome in order to be integrated to create a novel tumour control probability (TCP) model which links MR-based QIB with outcome as the basis for future external validation and subsequent interventions such as focal dose escalation (bio-boost, dose painting). Finally, methodological results on quantitative MRI techniques as well as knowledge gained in this project on MR-based response assessment and TCP modelling will be transferred to other projects of this joint application including different cancer types and clinical applications in the context of MR-guided RT.

该研究项目的重点是使用杂交的磁性磁共振成像（MRI）和功能性肿瘤特征。 MR-LINAC启动的MR - 低音定量成像生物标志物（QIB），例如明显的扩散（ADC），T1-，T2和T2*-Mapping Inc患者（RT）。所有QIB作为RT的肿瘤体积，在随后的临床研究的情况下，将研究定量的MRI测量与最新的MR扫描仪的可比性。 QIB的潜在程序将被整合起来，以创建新的肿瘤控制概率（TCP）模型，该模型将基于MR的QIB与结果作为未来验证的基础，例如焦点剂量升级（Bio-Boost，剂量绘画）定量MRI技术是该项目在基于MR的储备和TCP建模的项目中获得的知识，将是应用程序的其他项目，包括不同的癌症类型类型和在MR指导RT的背景下进行的癌症类型和临床应用。